Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder

Next Previous
Trial Profile

An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seltorexant (Primary) ; Diphenhydramine
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Janssen-Cilag

Most Recent Events

  • 01 Jun 2016 Data from this trial will be presented at the Jefferies 2016 Healthcare Conference, according to a Minerva Neurosciences media release.
  • 11 Mar 2016 According to a Minerva Neurosciences media release, based on the results of this trial, the company plans to initiate another phase IIb study of MIN-202 (see CTP 700269173).
  • 07 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top